3 Anticipated Major Milestones in 2026 and the First Half of 2027 Global Pipeline Expected Clinical Developments and Data Readouts Zocilurtatug Pelitecan (zoci, DLL3-Targeting ADC; formerly ZL-1310) • First-Line Extensiv

ZNTL

Azenosertib; rapid oral + trial-in-progress poster · source

Each presenter is sourced to the company's own filing or release naming this meeting; this is not the organiser's programme, and abstract titles are embargoed until the organiser publishes them.

About · Corrections · Changelog · Glossary · Methodology

Not affiliated with ESMO or its organizer. pdufa.bio is an independent publication with no affiliation with, endorsement by, sponsorship by, or connection to the U.S. Food and Drug Administration or any other government agency. “FDA”, “PDUFA” and all company, drug and ticker names are used descriptively and remain the property of their respective owners.

Informational and educational purposes only. Not investment advice. Nothing on this page is investment, legal, tax or medical advice, or an offer or solicitation to buy or sell any security. pdufa.bio is not a registered investment adviser or broker-dealer and does not recommend trades or publish individual-drug approval probabilities. Verify every date and outcome against primary FDA, SEC or company filings. Data is provided as is, without warranty of any kind, and past behaviour does not predict future outcomes.

© 2026 pdufa.bio. All rights reserved.

What presenting companies' shares did, across the whole study

Across 1,425 presentations at major medical meetings from 2017 to 2026, the median presenting company's stock moved −0.03% in the 30 trading days before the meeting (49.8% rose) and −1.59% in the 5 trading days after (39.4% rose). Small caps: +2.75% before (n=298); nano caps: −7.86% (n=108). The middle half of all presenters ranged from −10.41% to +13.58%. The study is anchored on the meeting start date, not on the abstract release; the true catalyst may be earlier. This measures what happened; it is not a forecast for any company. Full study, with the method and its limits.

How ESMO stocks have traded historically

Median share-price move around a presentation, measured across 192 ESMO presentations in our study (2017-2026).

30 days before-3.33% 39% rose · n=192

10 days before-1.96% 38% rose · n=192

Presentation day-0.34% 47% rose · n=192

5 days after-1.29% 39% rose · n=192

10 days after-1.34% 41% rose · n=192

By company size (10-day run-up → 5 days after)

Micro ($50-300M)-5.08% into it → -1.95% after n=30

Small ($300M-$2B)-5.42% into it → -0.96% after n=26

Mid ($2-10B)-1.81% into it → -3.00% after n=17

Large (>$10B)-1.45% into it → -0.33% after n=65

Read the whole row, not just the first line: across this study stocks have drifted up into these meetings and down out of them, and the effect is largest in the smallest companies. Medians are shown because a handful of large moves pulls an average away from the typical case. This is a historical distribution for a cohort of companies, not a forecast for any single company, and not investment advice. Methodology and the full study.

FAQ

When is ESMO 2026?

European Society for Medical Oncology Congress 2026 runs October 23-27, 2026 in Madrid, ES. The date comes from the organiser's own announcement; check the organiser's site for the final programme.

Which biotech companies are presenting at ESMO 2026?

From company filings and releases we have sourced 18 presenter commitments for this edition: BLRX, CELC, CMPX, EIKN, EVAX, IDYA, IMMP, IMTX, KTTA, MGNX, MOLN, MRNA, NBP, NUVB, ORIC, XNCR, ZLAB, ZNTL. This is not the organiser's programme -- only presentations companies have themselves announced, each linked to its filing on the conferences page.

How do biotech stocks typically trade around ESMO?

In our study of 192 ESMO presentations (2017-2026), the median stock moved -1.96% over the 10 trading days before the presentation (38% of them rose), -0.34% on the day itself, and -1.29% over the 5 trading days after. The pattern across the whole study is a drift up into these meetings and down out of them, strongest in the smallest companies. That is a historical distribution for a cohort, not a prediction for any one company, and not investment advice.

Why do medical conference dates matter for biotech stocks?

Trial results are often presented first at medical meetings, so a company's announced presentation is a dated, public catalyst. We publish a study of how biotech stocks have historically traded into conference presentations on the research page; it is historical measurement, not a prediction, and none of this is investment advice.